Eptifibatide is noninferior to abciximab: implications for clinical practice.

King A

首页> 外文期刊>Nature reviews. Cardiology >Eptifibatide is noninferior to abciximab: implications for clinical practice.

【24h】

Eptifibatide is noninferior to abciximab: implications for clinical practice.

机译：依替非巴肽不逊于阿昔单抗：对临床实践的意义。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

The glycoprotein IIb/IIIa (GPIIb/ IIIa) inhibitors eptifibatide and abciximab have comparable efficacy and safety in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). These findings, from a randomized trial and a registry study, are reported in two papers published in the Journal of the American College of Cardiology (JACC).

机译：糖蛋白IIb / IIIa（GPIIb / IIIa）抑制剂eptifibatide和abciximab在接受原发性经皮冠状动脉介入治疗（PCI）的ST段抬高型心肌梗塞（STEMI）患者中具有相当的疗效和安全性。这些发现来自一项随机试验和一项登记研究，并发表在《美国心脏病学会杂志》（JACC）上的两篇论文中。

著录项

来源
《Nature reviews. Cardiology》 |2010年第10期|共1页
作者
King A;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Eptifibatide is noninferior to abciximab: implications for clinical practice. [J] . King A Nature reviews. Cardiology . 2010,第10期

机译：依替非巴肽不逊于阿昔单抗：对临床实践的意义。
2. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients [J] . KS Rathod, S Antoniou, P Avari, JRSM Cardiovascular Disease . 2017,第4期

机译：在原发性ST段抬高型心肌梗死的经皮冠状动脉介入治疗中使用依普替巴肽可节省大量成本，并获得与阿昔单抗相似的临床结果：一项针对3863名患者的观察性队列研究
3. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions. [J] . Midei MG, Coombs VJ, Lowry DR, Cardiology . 2007,第3期

机译：比较在经皮冠状动脉介入治疗的ST抬高急性心肌梗死患者中依替非巴肽和阿昔单抗的临床疗效。
4. The Long-Term Clinical Results of a Platelet Glycoprotein Ilb/IIIa Receptor Blocker (Abciximab: ReoPro~R)-Coated Stent in Patients with Coronary Artery Disease [C] . W. Kim, M.H. Jeong, Y.J. Hong, International Congress on Thrombosis . 2004

机译：冠状动脉疾病患者的血小板糖蛋白ILB / IIIA受体阻滞剂（Abciximab：Reopro〜R）涂层支架的长期临床结果
5. Modeling the patient and anesthesia machine system: Implications for equipment design and clinical practice. [D] . Beams, David Michael. 1997

机译：对患者和麻醉机系统建模：对设备设计和临床实践的影响。
6. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients [O] . KS Rathod, S Antoniou, P Avari, 2017

机译：当在3863例患者的经皮冠状动脉介入治疗中进行首次经皮冠状动脉介入治疗时使用埃替非巴肽可节省大量成本并获得与abciximab类似的临床结果
7. Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) [O] . Åkerblom Axel, James Stefan K., Koutouzis Michail, 2010

机译：在SCAAR的主要经皮冠状动脉介入治疗结果中，Eptifibatide不逊于Abciximab（瑞典冠状动脉造影和血管成形术注册处）
8. Economic and Development Implications of Transportation Disinvestment. A Synthesis of Highway Practice. A Synthesis of Highway Practice. [R] . Duncan, C., Weisbrod, G. 2015

机译：交通运输投资的经济和发展影响。公路实践综合。公路实践综合。

Eptifibatide is noninferior to abciximab: implications for clinical practice.

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅